Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H17FN4O2 |
| Molecular Weight | 388.3944 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=C(NC(=O)N[C@H]2N=C(C3=CC=CC=C3)C4=C(NC2=O)C=CC=C4)C=CC=C1
InChI
InChIKey=MTPVBMVUENFFLL-HXUWFJFHSA-N
InChI=1S/C22H17FN4O2/c23-16-11-5-7-13-18(16)25-22(29)27-20-21(28)24-17-12-6-4-10-15(17)19(26-20)14-8-2-1-3-9-14/h1-13,20H,(H,24,28)(H2,25,27,29)/t20-/m1/s1
| Molecular Formula | C22H17FN4O2 |
| Molecular Weight | 388.3944 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 18:31:57 GMT 2025
by
admin
on
Tue Apr 01 18:31:57 GMT 2025
|
| Record UNII |
6NF9HI6D98
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID101125220
Created by
admin on Tue Apr 01 18:31:57 GMT 2025 , Edited by admin on Tue Apr 01 18:31:57 GMT 2025
|
PRIMARY | |||
|
RSV-604
Created by
admin on Tue Apr 01 18:31:57 GMT 2025 , Edited by admin on Tue Apr 01 18:31:57 GMT 2025
|
PRIMARY | Primary Objectives:Pilot Study: A preliminary assessment of the exposure and safety of oral A-60444 in post-stem cell transplant patients with RSV infection.Main Study: To determine the antiviral effect of oral A-60444 versus placebo in post-stem cell transplant patients with RSV infection and to assess the safety of oral A-60444 in post-stem cell transplant patients with RSV infection.Secondary Objectives:To study the pharmacokinetics of A-60444 in the presence of concomitant medications such as immunosuppressants and antifungals, in post-stem cell transplant patients with RSV infection. | ||
|
5279172
Created by
admin on Tue Apr 01 18:31:57 GMT 2025 , Edited by admin on Tue Apr 01 18:31:57 GMT 2025
|
PRIMARY | |||
|
DB15197
Created by
admin on Tue Apr 01 18:31:57 GMT 2025 , Edited by admin on Tue Apr 01 18:31:57 GMT 2025
|
PRIMARY | |||
|
6NF9HI6D98
Created by
admin on Tue Apr 01 18:31:57 GMT 2025 , Edited by admin on Tue Apr 01 18:31:57 GMT 2025
|
PRIMARY | |||
|
300000041381
Created by
admin on Tue Apr 01 18:31:57 GMT 2025 , Edited by admin on Tue Apr 01 18:31:57 GMT 2025
|
PRIMARY | |||
|
676128-63-5
Created by
admin on Tue Apr 01 18:31:57 GMT 2025 , Edited by admin on Tue Apr 01 18:31:57 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
XTT assay with indexnstrain RSS
EC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antiviral, Benzodiazepinone, Phenylurea compound, Small molecule; Mechanism of Action: Nucleocapsid protein inhibitor, Virus replication inhibitor; Highest Development Phase: Discontinued for Respiratory syncytial virus infection; Most Recent Events: 16 Nov 2010 RSV 604 is still in active development, 02 Oct 2008 Preclinical trials in Respiratory syncytial virus infections (in infants) in United Kingdom (PO), 31 Oct 2006 Phase-I clinical trials in Respiratory syncytial virus infections in volunteers United Kingdom (IV)
|
